Chapare hemorrhagic fever (CHHF) is a type of viral infectious disease that is caused by chapare virus. It belongs to the Arenaviridae family. This is an animal borne virus and zoonotic. CHHF is an acute viral hemorrhagic fever which is typically characterised by arthralgia, myalgia, fever, abdominal pain, skin rashes, vomiting, bleeding gums and multiple hemorrhagic signs. It typically causes a hemorrhagic fever similar to Ebola along with pain behind the eyes.
In 2020, because of the spread of COVID-19, the U.S. Centers for Disease Control and Prevention (CDC) started researching other deadly viruses, and discovered the chapare virus. The virus can be transmitted from human to human in direct contact with an infected rodent. It was first witnessed in Bolivia, where it initially resulted in a pandemic and later came under control in no time. Increase in the occurrence of infectious disease, rising healthcare expenditure boost the market growth.
Data Bridge Market Research analyses a growth rate in the chapare hemorrhagic fever (CHHF) market in the forecast period 2023-2030. The expected CAGR of chapare hemorrhagic fever (CHHF) market is tend to be around 4.50% in the mentioned forecast period. The market value is USD 1.54 billion in 2022, and it would grow upto USD 2.2 billion by 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
North America is the dominating region due to the rising occurrence of haemophilus influenzae infection and advanced healthcare facilities.
Read Full Report Summary @ https://www.databridgemarketresearch.com/reports/global-chapare-hemorrhagic-fever-chhf-market
Asia-Pacific is considered the growing region because of the higher cases of cardiovascular diseases and rapidly aging population.
Key players operating in the chapare hemorrhagic fever (CHHF) market include:
Novartis AG (Switzerland)
Endo International Inc (Ireland)
Teva Pharmaceutical Industries Ltd (Israel)
Glenmark Pharmaceuticals Ltd (India)
Cipla Inc (India)
Dr Reddy's Laboratories Ltd (India)
Abbott (U.S.)
F. Hoffmann-La Roche Ltd (Switzerland)
Pfizer Inc (U.S.)
Zydus Group (India)
Lupin (India)
Amorphex Therapeutics Holdings, Inc (U.S.)
Bausch Health Companies Inc. (Canada)
WEX Pharmaceuticals Inc (Canada)
Zynerba Pharmaceuticals, Inc (U.S.)
Estrellas Life Sciences Private Limited (U.S.)
About Data Bridge Market Research:
An absolute way to forecast what future holds is to comprehend the trend today!
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.
Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.
Contact Us:-
Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475